Meeting
2024 ASCO Annual Meeting
A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.
Authors
Nehal J. Lakhani
START Midwest, Grand Rapids, MI
Nehal J. Lakhani , Omid Hamid , Irene Brana , M. Julia Lostes-Bardaji , Pablo Gajate , Maria Pilar Lopez-Criado , Paul Swiecicki , Maria J. de Miguel , Marta Gil-Martin , Victor Moreno , Aixa Elena Soyano Muller , Ana Gonzalez Ortiz , Dylan Sun , Dimple Modi , Wenjun Zheng , Vladimir Jankovic , Mark Salvati , Matthew G. Fury , Mihaela C. Cristea
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Clinical Trial Registration Number
NCT04465487
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2650)
DOI
10.1200/JCO.2024.42.16_suppl.2650
Abstract #
2650
Poster Bd #
129
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2023 ASCO Quality Care Symposium
Non-elective inpatient anti-cancer therapy for solid tumors: To treat or not to treat?
First Author: Chloe Shevlin
Poster
2023 ASCO Breakthrough
AFM24 in combination with autologous NK cells (SNK01) in patients with advanced/metastatic epidermal growth factor receptor (EGFR) expressing solid tumors: Initial results from the phase 1 dose‑escalation study.
First Author: Anthony B. El-Khoueiry
Poster
2023 ASCO Annual Meeting
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.
First Author: Timothy J. Panella